Kazia Therapeutics Updates on Clinical Trial Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 27 2026
0mins
Source: PRnewswire
- Significant Clinical Responses: In the ongoing Phase 1b trial, three patients with late-stage metastatic triple-negative breast cancer treated with paxalisib demonstrated meaningful clinical responses, including two partial responses and one confirmed complete metabolic response, indicating the potential efficacy of this therapy.
- Trial Design and Patient Selection: This multi-center, open-label randomized study, initiated in June 2025, aims to evaluate the safety and preliminary efficacy of paxalisib in combination with standard treatment regimens, with eligibility requiring PD-L1 positive disease, ensuring scientific rigor and clinical relevance.
- Adverse Event Monitoring: Approximately 75% of adverse events reported during treatment were assessed as unrelated to paxalisib, with most being mild to moderate, demonstrating the drug's good tolerability and laying a foundation for future clinical applications.
- Future Development Plans: Kazia plans to activate two additional clinical trial sites by April 2026 and anticipates enrolling 12 patients by the end of 2026, further advancing paxalisib's application in broader breast cancer populations, showcasing the company's long-term commitment to this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KZIA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KZIA
Wall Street analysts forecast KZIA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.670
Low
18.00
Averages
19.00
High
20.00
Current: 12.670
Low
18.00
Averages
19.00
High
20.00
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kazia Plans to Increase Patient Enrollment in Clinical Trial
- Patient Enrollment Expansion: Kazia Therapeutics announced plans to increase patient enrollment in its Phase 1b clinical trial for advanced triple-negative breast cancer from 12 to 36, aiming to further evaluate the safety and tolerability of paxalisib in combination with standard therapies, thereby providing more effective treatment options for hard-to-treat cancer patients.
- Clinical Data Support: Based on the encouraging safety and tolerability data observed to date, Kazia plans to optimize dosing and preliminary efficacy assessments through this expanded sample size, which is expected to yield more meaningful objective response rates and progression-free survival data, further advancing the company's research in oncology.
- Scientific Progress Presentation: Although the company planned to present scientific progress at ASCO 2026, it decided to withdraw abstracts to protect its intellectual property, indicating a strong emphasis on IP protection while reflecting strategic considerations in its clinical research.
- Future Outlook: Kazia anticipates sharing additional clinical and translational updates throughout 2026 and into 2027, further solidifying its market position in cancer treatment, particularly regarding the potential of paxalisib in addressing the challenges of treating advanced triple-negative breast cancer.
See More
Kazia Appoints New Chief Scientific Officer
- Executive Appointment: Kazia Therapeutics has appointed Dr. Sudha Rao as Chief Scientific Officer, bringing over 20 years of expertise in translational epigenetics and clinical development, which will enhance the execution of the company's oncology platform strategy.
- R&D Leadership: Dr. Rao will lead all research and development activities, advancing the company's drug pipeline, particularly focusing on paxalisib targeting the PI3K/mTOR pathway, aiming to enhance precision medicine capabilities and accelerate novel therapy development.
- Patents and Innovation: As the lead inventor on 39 international patents, Dr. Rao's scientific contributions have laid the groundwork for Kazia's strategy, particularly in epigenetic reprogramming, driving innovation in cancer treatment.
- Market Potential: Kazia's paxalisib has received FDA orphan drug and fast track designations and is undergoing multiple clinical trials, demonstrating potential in treating various cancers, with Dr. Rao's addition expected to further strengthen the company's market competitiveness.
See More
Kazia Acquires SETDB1-Targeted Drug Development Platform
- Innovative Drug Platform: Kazia Therapeutics has in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer, utilizing an AI-integrated drug discovery engine to accelerate candidate generation, which is expected to significantly enhance the company's competitiveness in the tumor immunotherapy sector.
- Lead Drug Candidate: The lead candidate MSETC is a highly selective bicyclic peptide designed to target the disease-associated SETDB1 complex, aiming to restore immune signaling in tumors resistant to immunotherapy, potentially improving outcomes for patients with various cancers.
- Significant Market Potential: The global epigenetic therapeutics market is estimated to generate annual revenues between $15 billion and $20 billion, and Kazia's SETDB1 program addresses a major unmet need in treatment-refractory cancers, which could yield substantial market share and revenue growth for the company.
- Clear Development Path: Kazia plans to advance the SETDB1 program to IND readiness within 18 months at an estimated cost of $6 million, leveraging shared CRO resources and coordinated study designs, which is expected to achieve significant execution efficiencies and strengthen the company's strategic position in cancer treatment.
See More
Kazia Acquires SETDB1-targeted Drug Development Platform
- Innovative Drug Platform: Kazia Therapeutics has in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer, utilizing an AI-integrated drug discovery engine to rapidly generate candidates, which is expected to significantly accelerate the drug development process for cancer therapies.
- Lead Drug Candidate: The lead candidate, MSETC, is a highly selective bicyclic peptide designed to target the disease-associated SETDB1 complex, which is anticipated to restore immune signaling in tumors resistant to immunotherapy, showcasing substantial clinical application potential.
- Multi-Layered Tumor Control: Kazia's pipeline spans three complementary layers of cancer control, including epigenetic regulation, transcriptional reprogramming, and protein-level control, aimed at fundamentally addressing tumor resistance mechanisms and creating new opportunities for combination therapies across various cancer types.
- Broad Market Potential: The global epigenetic therapeutics market is estimated to generate annual revenues between $15 billion and $20 billion, and Kazia's SETDB1 program is positioned to meet a significant unmet need in treating aggressive, treatment-refractory cancers, thereby advancing the company's strategic positioning in the rapidly growing oncology sector.
See More
Kazia's NDL2 Therapy Significantly Reduces Tumor Volume
- Significant Tumor Volume Reduction: In murine triple-negative breast cancer preclinical models, NDL2 as a monotherapy reduced primary tumor volume by 49%, demonstrating its efficacy and potential as a standalone treatment option for future therapies.
- Combined Therapy Effectiveness: When combined with anti-PD-1 therapy, NDL2 reduced primary tumor volume by 73%, indicating that this combination therapy has significant potential to enhance anti-tumor activity and improve patient outcomes.
- Positive Results in Lung Metastasis Patients: In patients with lung metastases, the combination of NDL2 and anti-PD-1 therapy resulted in a 50% reduction in primary tumor volume, providing new hope for treating metastatic cancer and potentially altering clinical treatment strategies.
- Positive Market Reaction: Kazia Therapeutics' shares rose over 6% in pre-market trading on Friday, reflecting investor optimism regarding the new data on NDL2 and indicating strong market confidence in the company's future prospects.
See More
Kazia Launches First-in-Class Nuclear PD-L1 Degrader NDL2
- Novel Therapeutic Target: Kazia Therapeutics announces NDL2 as the first nuclear PD-L1 degrader, targeting a previously unaddressed mechanism of immunotherapy resistance, potentially transforming cancer treatment paradigms.
- Significant Efficacy Data: In murine triple-negative breast cancer models, NDL2 reduced primary tumor volume by 49% as monotherapy and 73% in combination with anti-PD-1, demonstrating its robust anti-tumor activity.
- Safety and Pharmacokinetics: NDL2 showed no toxicity in preclinical trials, preserving immune checkpoint function at the cell surface, indicating its potential safety and efficacy in clinical applications.
- Future Development Outlook: Kazia plans to initiate first-in-human clinical trials in 2027 targeting immunotherapy-refractory solid tumors, with NDL2's development expected to create strategic partnership opportunities and long-term value.
See More
Kazia Plans to Increase Patient Enrollment in Clinical Trial
- Patient Enrollment Expansion: Kazia Therapeutics announced plans to increase patient enrollment in its Phase 1b clinical trial for advanced triple-negative breast cancer from 12 to 36, aiming to further evaluate the safety and tolerability of paxalisib in combination with standard therapies, thereby providing more effective treatment options for hard-to-treat cancer patients.
- Clinical Data Support: Based on the encouraging safety and tolerability data observed to date, Kazia plans to optimize dosing and preliminary efficacy assessments through this expanded sample size, which is expected to yield more meaningful objective response rates and progression-free survival data, further advancing the company's research in oncology.
- Scientific Progress Presentation: Although the company planned to present scientific progress at ASCO 2026, it decided to withdraw abstracts to protect its intellectual property, indicating a strong emphasis on IP protection while reflecting strategic considerations in its clinical research.
- Future Outlook: Kazia anticipates sharing additional clinical and translational updates throughout 2026 and into 2027, further solidifying its market position in cancer treatment, particularly regarding the potential of paxalisib in addressing the challenges of treating advanced triple-negative breast cancer.
See More
Kazia Appoints New Chief Scientific Officer
- Executive Appointment: Kazia Therapeutics has appointed Dr. Sudha Rao as Chief Scientific Officer, bringing over 20 years of expertise in translational epigenetics and clinical development, which will enhance the execution of the company's oncology platform strategy.
- R&D Leadership: Dr. Rao will lead all research and development activities, advancing the company's drug pipeline, particularly focusing on paxalisib targeting the PI3K/mTOR pathway, aiming to enhance precision medicine capabilities and accelerate novel therapy development.
- Patents and Innovation: As the lead inventor on 39 international patents, Dr. Rao's scientific contributions have laid the groundwork for Kazia's strategy, particularly in epigenetic reprogramming, driving innovation in cancer treatment.
- Market Potential: Kazia's paxalisib has received FDA orphan drug and fast track designations and is undergoing multiple clinical trials, demonstrating potential in treating various cancers, with Dr. Rao's addition expected to further strengthen the company's market competitiveness.
See More
Kazia Acquires SETDB1-Targeted Drug Development Platform
- Innovative Drug Platform: Kazia Therapeutics has in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer, utilizing an AI-integrated drug discovery engine to accelerate candidate generation, which is expected to significantly enhance the company's competitiveness in the tumor immunotherapy sector.
- Lead Drug Candidate: The lead candidate MSETC is a highly selective bicyclic peptide designed to target the disease-associated SETDB1 complex, aiming to restore immune signaling in tumors resistant to immunotherapy, potentially improving outcomes for patients with various cancers.
- Significant Market Potential: The global epigenetic therapeutics market is estimated to generate annual revenues between $15 billion and $20 billion, and Kazia's SETDB1 program addresses a major unmet need in treatment-refractory cancers, which could yield substantial market share and revenue growth for the company.
- Clear Development Path: Kazia plans to advance the SETDB1 program to IND readiness within 18 months at an estimated cost of $6 million, leveraging shared CRO resources and coordinated study designs, which is expected to achieve significant execution efficiencies and strengthen the company's strategic position in cancer treatment.
See More
Kazia Acquires SETDB1-targeted Drug Development Platform
- Innovative Drug Platform: Kazia Therapeutics has in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer, utilizing an AI-integrated drug discovery engine to rapidly generate candidates, which is expected to significantly accelerate the drug development process for cancer therapies.
- Lead Drug Candidate: The lead candidate, MSETC, is a highly selective bicyclic peptide designed to target the disease-associated SETDB1 complex, which is anticipated to restore immune signaling in tumors resistant to immunotherapy, showcasing substantial clinical application potential.
- Multi-Layered Tumor Control: Kazia's pipeline spans three complementary layers of cancer control, including epigenetic regulation, transcriptional reprogramming, and protein-level control, aimed at fundamentally addressing tumor resistance mechanisms and creating new opportunities for combination therapies across various cancer types.
- Broad Market Potential: The global epigenetic therapeutics market is estimated to generate annual revenues between $15 billion and $20 billion, and Kazia's SETDB1 program is positioned to meet a significant unmet need in treating aggressive, treatment-refractory cancers, thereby advancing the company's strategic positioning in the rapidly growing oncology sector.
See More
Kazia's NDL2 Therapy Significantly Reduces Tumor Volume
- Significant Tumor Volume Reduction: In murine triple-negative breast cancer preclinical models, NDL2 as a monotherapy reduced primary tumor volume by 49%, demonstrating its efficacy and potential as a standalone treatment option for future therapies.
- Combined Therapy Effectiveness: When combined with anti-PD-1 therapy, NDL2 reduced primary tumor volume by 73%, indicating that this combination therapy has significant potential to enhance anti-tumor activity and improve patient outcomes.
- Positive Results in Lung Metastasis Patients: In patients with lung metastases, the combination of NDL2 and anti-PD-1 therapy resulted in a 50% reduction in primary tumor volume, providing new hope for treating metastatic cancer and potentially altering clinical treatment strategies.
- Positive Market Reaction: Kazia Therapeutics' shares rose over 6% in pre-market trading on Friday, reflecting investor optimism regarding the new data on NDL2 and indicating strong market confidence in the company's future prospects.
See More
Kazia Launches First-in-Class Nuclear PD-L1 Degrader NDL2
- Novel Therapeutic Target: Kazia Therapeutics announces NDL2 as the first nuclear PD-L1 degrader, targeting a previously unaddressed mechanism of immunotherapy resistance, potentially transforming cancer treatment paradigms.
- Significant Efficacy Data: In murine triple-negative breast cancer models, NDL2 reduced primary tumor volume by 49% as monotherapy and 73% in combination with anti-PD-1, demonstrating its robust anti-tumor activity.
- Safety and Pharmacokinetics: NDL2 showed no toxicity in preclinical trials, preserving immune checkpoint function at the cell surface, indicating its potential safety and efficacy in clinical applications.
- Future Development Outlook: Kazia plans to initiate first-in-human clinical trials in 2027 targeting immunotherapy-refractory solid tumors, with NDL2's development expected to create strategic partnership opportunities and long-term value.
See More
